ArticleOncology letters2025
Immunotherapy for primary squamous cell carcinoma of the liver: A case report.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Redefining Liver Transplantation Indications for Hepatic Malignancies in the Era of Precision Transplant Oncology: An Up-to-Date Narrative Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study reports an exceedingly rare case of primary squamous cell carcinoma of the liver (PSCCL), a malignancy that has been documented in only ~30 cases worldwide, with both diagnosis and treatment presenting significant challenges. A 72-year-old man presented with right upper abdominal discomfort was admitted to Shaanxi Provincial Cancer Hospital (Xi'an, China). Computed tomography (CT) imaging revealed a space-occupying lesion in the liver. A subsequent percutaneous liver biopsy confirmed a diagnosis of PSCCL. Positron emission tomography/CT was performed to exclude metastasis from other primary sites and confirmed the diagnosis of PSCCL. The patient received combination therapy of envafolimab and albumin-paclitaxel plus cisplatin. Telephone follow-up continued until December 2024 (a total of 18 months), during which the patient achieved and maintained a sustained partial response. The uniqueness of the present case lies in the patient's receipt of an innovative therapeutic regimen combining envafolimab with albumin-paclitaxel and cisplatin, achieving a sustained partial response over an 18-month follow-up period. This outcome not only offers novel insights for the clinical management of PSCCL but also underscores the importance of multidisciplinary comprehensive treatment in rare tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.